|
|
Article: Neuropathic Pain Market to Reach $3.5 Billion by 2014, Despite Generic Neurontin Launch.
- Article from:
- PR Newswire
- Article date:
- July 11, 2005
CopyrightCOPYRIGHT 2005 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
SAN FRANCISCO, July 11 /PRNewswire/ -- WWMR, Inc. has released the supplement to the 2004 edition of the highly regarded series of US Neuropathic Pain reports, which examines the effects of the entry of generic competition on Neurontin in the anticonvulsant market for Neuropathic Pain. Key events leading up to and surrounding the launch of the gabapentin generics, as well as Pfizer's efforts to bring a follow-on-to-Neurontin brand, Lyrica (pregabalin), into the market are detailed. Pfizer has sustained significant losses in Neurontin sales and prescription volume with the entry of generic gabpentin competition.
The U.S. market for drug treatment of major ...
Related newspaper, magazine, and journal articles:
|
|
Article: US neuropathic pain market set to double by 2018
Inpharma Weekly;
September 20, 2008 ;
422 words
...According to US Neuropathic Pain, a report released by WWMR, the US market for ... Cymbalta] for diabetic neuropathic pain in 2004. WWMR predicts a healthy ... billion. [Reference] WWMR Inc. US Neuropathic Pain Market Value Doubles ...
|
|